Fig. 2: Baseline and longitudinal concentrations of sLAG3 predict progression-free and overall survival in patients undergoing immune checkpoint blockade. | British Journal of Cancer

Fig. 2: Baseline and longitudinal concentrations of sLAG3 predict progression-free and overall survival in patients undergoing immune checkpoint blockade.

From: Soluble lymphocyte activation gene-3 (sLAG3) and CD4/CD8 ratio dynamics as predictive biomarkers in patients undergoing immune checkpoint blockade for solid malignancies

Fig. 2

Using the median sLAG3 to split patients into two groups (20.1 pg/ml), patients with concentration above the median show strongly impaired PFS (a) and OS (b) compared to patients with levels below this cut-off. The predictive potential of sLAG3 levels before therapy is even higher when applying an ideal cut-off value (23.04 pg/ml), with patients with concentrations below the ideal cut-off having a median PFS of 314 days (c) and surviving in median 547 days (d) compared to a PFS of 71 and an OS of 141 days for patients with levels above the cut-off. e–h Patients with sLAG3 concentrations above the ideal cut-off value (early time point: 43.24 pg/ml, late time point: 58.26 pg/ml) show a significantly shorter PFS and OS compared to patients with lower circulating sLAG3 levels during the course of ICI treatment.

Back to article page